ImmunityBio’s (IBRX) “Buy” Rating Reiterated at D. Boral Capital

ImmunityBio (NASDAQ:IBRX)‘s stock had its “buy” rating reissued by investment analysts at D. Boral Capital in a research note issued on Monday,Benzinga reports. They presently have a $30.00 target price on the stock.

IBRX has been the topic of several other reports. HC Wainwright restated a “buy” rating and set a $8.00 price objective on shares of ImmunityBio in a research note on Thursday, March 13th. BTIG Research began coverage on ImmunityBio in a research report on Friday, January 10th. They set a “buy” rating and a $6.00 price target on the stock. One investment analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $12.19.

ImmunityBio Stock Performance

Shares of NASDAQ IBRX opened at $3.14 on Monday. The stock has a 50 day moving average price of $3.13 and a 200 day moving average price of $3.60. The stock has a market capitalization of $2.68 billion, a PE ratio of -3.41 and a beta of 0.82. ImmunityBio has a 52 week low of $2.28 and a 52 week high of $10.53.

ImmunityBio (NASDAQ:IBRX) last released its quarterly earnings data on Monday, March 3rd. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.11. The company had revenue of $7.55 million during the quarter, compared to analyst estimates of $8.74 million. As a group, research analysts forecast that ImmunityBio will post -0.92 EPS for the current year.

Hedge Funds Weigh In On ImmunityBio

Several large investors have recently modified their holdings of the stock. Stephens Inc. AR bought a new stake in shares of ImmunityBio during the 4th quarter worth about $26,000. Captrust Financial Advisors bought a new stake in shares of ImmunityBio during the third quarter worth approximately $41,000. Cibc World Markets Corp acquired a new position in shares of ImmunityBio in the fourth quarter valued at approximately $35,000. Virtu Financial LLC bought a new position in shares of ImmunityBio during the third quarter worth approximately $51,000. Finally, Maia Wealth LLC acquired a new stake in ImmunityBio during the 4th quarter worth approximately $37,000. 8.58% of the stock is owned by institutional investors.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.